Please login to the form below

Not currently logged in
Email:
Password:

Cancer Drug Fund

This page shows the latest Cancer Drug Fund news and features for those working in and with pharma, biotech and healthcare.

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

combination with chemotherapy in England via the Cancer Drugs Fund (CDF). ... We are therefore pleased to be able to use the flexibility provided by the Cancer Drugs Fund to recommend it while further data on its clinical effectiveness is collected,”

Latest news

  • Kisqali combination follows Verzenio onto Cancer Drugs Fund Kisqali combination follows Verzenio onto Cancer Drugs Fund

    Drug must prove its value via managed access route. Novartis’ Kisqali has been recommended for use on the Cancer Drugs Fund (CDF) for second line use in combination with fulvestrant in ... Ibrance and Kisqali gained NICE approval for first line

  • NICE lung cancer backing for Keytruda is biggest expansion yet NICE lung cancer backing for Keytruda is biggest expansion yet

    NICE has, however, only given the green light to MSD's drug via the Cancer Drugs Fund (CDF), as there isn’t enough evidence yet for routine NHS use. ... This drug combination has shown significant benefits for some patients in clinical trials, helping

  • NICE turns down Opdivo for adjuvant melanoma therapy NICE turns down Opdivo for adjuvant melanoma therapy

    BMS drug currently only licensed treatment in this setting. Bristol-Myers Squibb’s efforts to push the use of Opdivo earlier in the course of melanoma treatment have hit a snag ... It also says it cannot recommend the drug for use within the Cancer

  • Keytruda cleared for frontline lung cancer in England - but only after another pricing deal Keytruda cleared for frontline lung cancer in England - but only after another pricing deal

    Keytruda first drug to exit Cancer Drugs Fund and go through Budget Impact Test. ... This means it will now be removed from the ‘managed access’ Cancer Drugs Fund (CDF), the first drug to achieve this since the remodelled system was launched two

  • NICE U-turn on Opdivo for kidney cancer NICE U-turn on Opdivo for kidney cancer

    guidance. Opdivo (nivolumab) is now set to be recommended as a second-line treatment on the NHS in England and Wales almost immediately as the Cancer Drugs Fund will support the ... happy that NICE has made this recommendation for patients with advanced

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics